| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e378824e3997f0d55c33811189f4ad20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8a0748996704577980b7806fd22ade8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9985529ee812119b76fd420587d90ff4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62551f55b4bdada5a39671e62ec0d7f4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
| filingDate |
2010-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ed503b3ef005a86f3ec87bc948c2b7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_673d7e8a60c8bcd547ace8780aad0d13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b2811f4cc880f04299efc15cb83639f |
| publicationDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010132562-A2 |
| titleOfInvention |
Transdermal delivery of metformin |
| abstract |
Transdermal metformin is an effective alternative treatment modality in patients with insulin resistance who are unable to tolerate other oral anti-diabetic medications. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal metformin is its ability to bypass the gastrointestinal system. This allows the drug to not have the gastrointestinal side-effects associated with oral metformin. A surprising advantage of using transdermal metformin in accordance with this disclosure is a 90% decrease in dosage from the oral preparation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109414385-A |
| priorityDate |
2009-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |